Stefan Reiter

BorsodChem Zrt. manufactures and processes chemical and plastic raw materials. It offers isocyanates, polyvinyl chloride resins, base and specialty chemicals, and chlorinated alkali products. The company was founded in 1949 and is headquartered in Kazincbarcika, Hungary.

Creditanstalt-Investment Bank AG operates as an investment bank. The private company is based in Vienna, Austria.

Part of Collegia Privatstiftung, VCP Finanz Holding Vagyonkezelö Kft is a Hungarian Budapest-based company. VCP Finanz Holding Vagyonkezelö Kft provides investment services. Christian Riener has been the CEO of the company since 2007.

SpeedInvest GmbH (Speedinvest) was founded in 2011 and is headquartered in Vienna.

Collegia Privatstiftung is a private foundation that functions as a private equity fund. Through its subsidiaries, it provides funds and invests in private companies within Europe. The foundation was founded in 2000 and is headquartered in Vienna, Austria

Ringier doo provides newspaper publishing services. It markets its newspaper under Blic, 24Hours and Allo and magazines under Blic Pulse and Blic Woman brands. The company was founded in 1996 and is headquartered in Belgrade, Serbia.

Onsight Ventures Management GmbH (Onsight Ventures) is a venture capital firm founded in 2021. The firm is headquartered in Innsbruck, Austria.

genEplanet doo provides genetic testing and research services. The company is based in Ljuljana, Slovenia. The Slovene company was founded in 2008 by Marko Bitenc. Marko Bitenc has been the CEO since 2008.

Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation.